BAC Collaborates with Sanofi Pasteur for Vaccine Purification

Article

The Bio Affinity Company BAC BV (Naarden, the Netherlands, www.bac.nl) has entered into an agreement with Sanofi Pasteur (Lyon, France, www.sanofipasteur.com), the vaccines arm of the Sanofi-Aventis Group, for the use of BAC's CaptureSelect customized affinity ligands for process-scale purification of some of its vaccine products.

The Bio Affinity Company BAC BV (Naarden, the Netherlands, www.bac.nl) has entered into an agreement with Sanofi Pasteur (Lyon, France, www.sanofipasteur.com), the vaccines arm of the Sanofi-Aventis Group, for the use of BAC’s CaptureSelect customized affinity ligands for process-scale purification of some of its vaccine products. Manufactured using a proprietary yeast-based expression system, that is completely animal-free, CaptureSelect ligands exploit the nature of Camelid single chain antibody fragments and are designed to provide enhanced stability and broad antigen-specific binding.
 

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Junevity Co-founder & CEO, John Hoekman, PhD
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Daniel Fischer, Tevard
Related Content
© 2025 MJH Life Sciences

All rights reserved.